MacroGenics Inc (MGNX) shareholders
Close on Nov 17, 2026Market cap $130.59MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BB Biotech AG Joint filing with Biotech Target N.V. (15.80%) | 9,929,963 | 15.80% | 13G (passive) amendment | Dec 31, 2024 |
| Bellevue Asset Management AG Joint filing with Bellevue Group AG (15.70%) | 9,929,963 | 15.70% | 13G (passive) | Jun 1, 2025 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.46%) | 6,012,000 | 9.46% | 13G (passive) amendment | Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 5,639,994 | 9.10% | 13G (passive) | Feb 14, 2024 |
| Armistice Capital, LLC Joint filing with Steven Boyd (7.88%) | 5,006,752 | 7.88% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 4,503,913 | 7.10% | 13G (passive) | Jun 30, 2026 |
| Israel A. Englander Joint filing with Millennium Management LLC (5.40%), Millennium Group Management LLC (5.40%) | 3,435,504 | 5.40% | 13G (passive) | Jun 1, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MGNX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 5,006,752 | 7.86% | $23.13M | −1,005,248 | 0.28% |
| BlackRock, Inc. | 4,679,229 | 7.35% | $21.62M | +3,516,083 | 0.00% |
| Vanguard Capital Management LLC | 2,656,010 | 4.17% | $12.27M | +2,157 | 0.00% |
| Renaissance Technologies LLC | 2,632,750 | 4.13% | $12.16M | −330,809 | 0.02% |
| Acadian Asset Management LLC | 2,542,643 | 3.99% | $11.74M | −1,357 | 0.01% |
| Bank Of America Corp /De/ | 2,488,252 | 3.91% | $11.50M | +86,438 | 0.00% |
| Two Sigma Investments, LP | 2,465,699 | 3.87% | $11.39M | −62,130 | 0.01% |
| Millennium Management LLC | 2,374,296 | 3.73% | $10.97M | −420,061 | 0.00% |
| Wasatch Advisors LP | 2,018,881 | 3.17% | $9.33M | +459,180 | 0.06% |
| Ra Capital Management, L.P. | 1,864,176 | 2.93% | $8.61M | – | 0.07% |
| Vanguard Portfolio Management LLC | 1,820,231 | 2.86% | $8.41M | +611,456 | 0.00% |
| Mackenzie Financial Corp | 1,642,626 | 2.58% | $7.59M | +1,045,184 | 0.01% |
| Marshall Wace, Llp | 1,616,220 | 2.54% | $7.47M | −409,306 | 0.01% |
| Geode Capital Management, LLC | 1,576,549 | 2.47% | $7.29M | +879,228 | 0.00% |
| Affinity Asset Advisors, LLC | 1,216,606 | 1.91% | $5.62M | +716,606 | 0.25% |
| D. E. Shaw & Co., Inc. | 1,062,991 | 1.67% | $4.91M | +4,567 | 0.00% |
| Jacobs Levy Equity Management, Inc | 1,002,274 | 1.57% | $4.63M | +561,131 | 0.02% |
| Connor, Clark & Lunn Investment Management Ltd. | 1,000,412 | 1.57% | $4.62M | +133,163 | 0.01% |
| State Street Corp | 863,663 | 1.36% | $3.99M | +569,976 | 0.00% |
| Goldman Sachs Group Inc | 558,001 | 0.88% | $2.58M | +284,523 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 122 | 49M | 76.4% | 38 / 34 | 29 / 25 | 12M | 6M |
| Q1 2026 | 109 | 43M | 67.8% | 32 / 29 | 28 / 10 | 14M | 6M |
| Q4 2025 | 89 | 40M | 62.7% | 13 / 30 | 26 / 24 | 12M | 18M |
| Q3 2025 | 104 | 47M | 73.5% | 17 / 30 | 26 / 24 | 5M | 6M |
| Q2 2025 | 112 | 48M | 75.9% | 26 / 27 | 34 / 42 | 6M | 11M |
| Q1 2025 | 128 | 54M | 84.7% | 19 / 36 | 42 / 18 | 4M | 6M |
| Q4 2024 | 128 | 56M | 88.1% | 23 / 40 | 38 / 19 | 5M | 5M |
| Q3 2024 | 124 | 56M | 88.0% | 14 / 38 | 47 / 35 | 8M | 8M |
| Q2 2024 | 147 | 61M | 96.4% | 27 / 52 | 49 / 42 | 16M | 21M |
| Q1 2024 | 163 | 66M | 100.0% | 41 / 55 | 50 / 19 | 17M | 14M |
| Q4 2023 | 142 | 63M | 99.4% | 31 / 47 | 48 / 16 | 11M | 5M |
| Q3 2023 | 127 | 58M | 91.1% | 13 / 45 | 46 / 17 | 3M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
92 funds held MGNX in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MGNX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,925,510 | 3.02% | $8.90M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,560,778 | 2.45% | $7.21M | 0.01% | Jun 30, 2026 |
| Wasatch Ultra Growth Fund | 1,117,456 | 1.75% | $5.16M | 1.12% | Jun 30, 2026 |
| Wasatch Micro Cap Fund | 771,218 | 1.21% | $3.56M | 0.53% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 683,332 | 1.07% | $2.52M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 649,399 | 1.02% | $3.00M | 0.00% | Jun 30, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 551,029 | 0.87% | $2.55M | 0.08% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 513,042 | 0.81% | $2.37M | 0.02% | Jun 30, 2026 |
| Small Company Growth Portfolio | 437,607 | 0.69% | $2.02M | 0.12% | Jun 30, 2026 |
| Vanguard Explorer Fund | 421,515 | 0.66% | $1.56M | 0.01% | Jul 31, 2026 |
| Nomura Healthcare Fund | 420,000 | 0.66% | $1.94M | 0.26% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 303,029 | 0.48% | $1.26M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 211,153 | 0.33% | $975.53K | 0.06% | Jun 30, 2026 |
| Fidelity SAI Small-Mid Cap Momentum Index Fund | 177,801 | 0.28% | $656.09K | 0.02% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 152,584 | 0.24% | $563.03K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eric Blasius Risser | President and CEO, Director | 77,169 | 0.12% | Feb 17, 2026 |
| Ezio Bonvini | Sr VP, Research & CSO | 201,349 | 0.32% | Oct 7, 2026 |
| Jeffrey Stuart Peters | Senior VP, GC, and Secretary | 0 | – | Aug 20, 2026 |
| Beth Ann Smith | VP, Controller & Treasurer | 13,204 | 0.02% | Feb 17, 2026 |
| James Karrels | SVP and CFO | 306,368 | 0.48% | Feb 17, 2026 |
| Thomas Spitznagel | Sr VP, Technical Ops | 38,543 | 0.06% | Feb 17, 2026 |
| Stephen L. Eck | Chief Medical Officer | 29,377 | 0.05% | Feb 19, 2025 |
| Emil Kuriakose | Director | – | – | Nov 3, 2026 |
| Michael Vasconcelles | Director | – | – | Nov 3, 2026 |
| William K. Heiden | Director | 114,750 | 0.18% | May 20, 2026 |
| Scott Koenig | Director | 1,294,720 | 2.03% | May 20, 2026 |
| Scott Thomas Jackson | Director | 14,750 | 0.02% | May 20, 2026 |
| Jay Philip Siegel | Director | 14,750 | 0.02% | May 20, 2026 |
| Karen Jean Ferrante | Director | 14,750 | 0.02% | May 20, 2026 |
| Federica F. O'Brien | Director | 14,750 | 0.02% | May 20, 2026 |
| Edward Hurwitz | Director | 1,752,820 | 2.75% | May 20, 2026 |
| Meenu Chhabra | Director | 14,750 | 0.02% | May 20, 2026 |
| Margaret Liu | Director | 14,750 | 0.02% | May 20, 2026 |
| David C. Stump | Director | 14,750 | 0.02% | May 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ezio Bonvini Sr VP, Research & CSO | Oct 6, 2026 | Option exercise | +8,000 | $2.60 | $20.80K | 193,799 |
| Jeffrey Stuart Peters Senior VP, GC, and Secretary | Aug 19, 2026 | Sale(10b5-1 plan) | −31,105 | $4.15 | $129.09K | 0 |
| Ezio Bonvini Sr VP, Research & CSO | Aug 17, 2026 | Option exercise | +40,000 | $2.60 | $104.00K | 185,799 |
| Jay Philip Siegel Director | May 18, 2026 | Option exercise | +3,750 | – | – | 14,750 |
| Karen Jean Ferrante Director | May 18, 2026 | Option exercise | +3,750 | – | – | 14,750 |
| Scott Thomas Jackson Director | May 18, 2026 | Option exercise | +3,750 | – | – | 14,750 |
| Margaret Liu Director | May 18, 2026 | Option exercise | +3,750 | – | – | 14,750 |
| Edward Hurwitz Director | May 18, 2026 | Option exercise | +3,750 | – | – | 47,824 |
| William K. Heiden Director | May 18, 2026 | Option exercise | +3,750 | – | – | 114,750 |
| David C. Stump Director | May 18, 2026 | Option exercise | +3,750 | – | – | 14,750 |
| Meenu Chhabra Director | May 18, 2026 | Option exercise | +3,750 | – | – | 14,750 |
| Federica F. O'Brien Director | May 18, 2026 | Option exercise | +3,750 | – | – | 14,750 |
| Thomas Spitznagel Sr VP, Technical Ops | Feb 15, 2026 | Tax withholding | −5,520 | $1.71 | $9.44K | 38,543 |
| Thomas Spitznagel Sr VP, Technical Ops | Feb 15, 2026 | Option exercise | +13,332 | – | – | 44,063 |
| Ezio Bonvini Sr VP, Research & CSO | Feb 15, 2026 | Tax withholding | −6,433 | $1.71 | $11.00K | 145,799 |
| Ezio Bonvini Sr VP, Research & CSO | Feb 15, 2026 | Option exercise | +16,665 | – | – | 152,232 |
| Scott Koenig Director | Feb 15, 2026 | Option exercise | +21,165 | – | – | 867,240 |
| Eric Blasius Risser President and CEO, Director | Feb 15, 2026 | Tax withholding | −6,433 | $1.71 | $11.00K | 77,169 |
| Eric Blasius Risser President and CEO, Director | Feb 15, 2026 | Option exercise | +16,665 | – | – | 83,602 |
| James Karrels SVP and CFO | Feb 15, 2026 | Tax withholding | −5,790 | $1.71 | $9.90K | 206,037 |
| James Karrels SVP and CFO | Feb 15, 2026 | Option exercise | +14,999 | – | – | 211,827 |
| Beth Ann Smith VP, Controller & Treasurer | Feb 15, 2026 | Option exercise | +1,095 | – | – | 13,204 |
| Beth Ann Smith VP, Controller & Treasurer | Feb 15, 2026 | Tax withholding | −423 | $1.71 | $723 | 12,781 |
| Jeffrey Stuart Peters Senior VP, GC, and Secretary | Feb 15, 2026 | Tax withholding | −5,147 | $1.71 | $8.80K | 31,105 |
| Jeffrey Stuart Peters Senior VP, GC, and Secretary | Feb 15, 2026 | Option exercise | +13,332 | – | – | 36,252 |
| Eric Blasius Risser President and CEO, Director | Feb 8, 2026 | Option exercise | +11,166 | – | – | 71,248 |
| Eric Blasius Risser President and CEO, Director | Feb 8, 2026 | Tax withholding | −4,311 | $1.81 | $7.80K | 66,937 |
| Scott Koenig Director | Feb 8, 2026 | Option exercise | +15,831 | – | – | 846,075 |
| Thomas Spitznagel Sr VP, Technical Ops | Feb 8, 2026 | Tax withholding | −3,186 | $1.81 | $5.77K | 30,731 |
| Thomas Spitznagel Sr VP, Technical Ops | Feb 8, 2026 | Option exercise | +8,999 | – | – | 33,917 |
| Beth Ann Smith VP, Controller & Treasurer | Feb 8, 2026 | Option exercise | +1,583 | – | – | 12,721 |
| Beth Ann Smith VP, Controller & Treasurer | Feb 8, 2026 | Tax withholding | −612 | $1.81 | $1.11K | 12,109 |
| Ezio Bonvini Sr VP, Research & CSO | Feb 8, 2026 | Tax withholding | −4,311 | $1.81 | $7.80K | 135,567 |
| Ezio Bonvini Sr VP, Research & CSO | Feb 8, 2026 | Option exercise | +11,166 | – | – | 139,878 |
| Jeffrey Stuart Peters Senior VP, GC, and Secretary | Feb 8, 2026 | Option exercise | +8,999 | – | – | 26,394 |
| Jeffrey Stuart Peters Senior VP, GC, and Secretary | Feb 8, 2026 | Tax withholding | −3,474 | $1.81 | $6.29K | 22,920 |
| James Karrels SVP and CFO | Feb 8, 2026 | Tax withholding | −3,860 | $1.81 | $6.99K | 196,828 |
| James Karrels SVP and CFO | Feb 8, 2026 | Option exercise | +9,999 | – | – | 200,688 |
| Eric Blasius Risser President and CEO, Director | Feb 7, 2026 | Tax withholding | −2,575 | $1.81 | $4.66K | 60,082 |
| Eric Blasius Risser President and CEO, Director | Feb 7, 2026 | Option exercise | +6,668 | – | – | 62,657 |
| Thomas Spitznagel Sr VP, Technical Ops | Feb 7, 2026 | Tax withholding | −2,485 | $1.81 | $4.50K | 24,918 |
| Thomas Spitznagel Sr VP, Technical Ops | Feb 7, 2026 | Option exercise | +6,001 | – | – | 27,403 |
| Beth Ann Smith VP, Controller & Treasurer | Feb 7, 2026 | Option exercise | +2,617 | – | – | 12,149 |
| Beth Ann Smith VP, Controller & Treasurer | Feb 7, 2026 | Tax withholding | −1,011 | $1.81 | $1.83K | 11,138 |
| Ezio Bonvini Sr VP, Research & CSO | Feb 7, 2026 | Option exercise | +7,001 | – | – | 131,415 |
| Ezio Bonvini Sr VP, Research & CSO | Feb 7, 2026 | Tax withholding | −2,703 | $1.81 | $4.89K | 128,712 |
| Jeffrey Stuart Peters Senior VP, GC, and Secretary | Feb 7, 2026 | Option exercise | +6,001 | – | – | 19,712 |
| Jeffrey Stuart Peters Senior VP, GC, and Secretary | Feb 7, 2026 | Tax withholding | −2,317 | $1.81 | $4.19K | 17,395 |
| James Karrels SVP and CFO | Feb 7, 2026 | Option exercise | +6,334 | – | – | 193,135 |
| James Karrels SVP and CFO | Feb 7, 2026 | Tax withholding | −2,446 | $1.81 | $4.43K | 190,689 |
| William K. Heiden Director | Aug 20, 2025 | Buy | +49,500 | $1.49 | $73.76K | 111,000 |
| William K. Heiden Director | Aug 19, 2025 | Buy | +50,500 | $1.52 | $76.76K | 61,500 |
| Scott Koenig Director | Aug 13, 2025 | Option exercise | +31,664 | – | – | 830,244 |
| Scott Koenig Director | Aug 13, 2025 | Option exercise | +21,165 | – | – | 798,580 |
| Scott Thomas Jackson Director | May 20, 2025 | Option exercise | +6,500 | – | – | 11,000 |
| David C. Stump Director | May 20, 2025 | Option exercise | +6,500 | – | – | 11,000 |
| Jay Philip Siegel Director | May 20, 2025 | Option exercise | +6,500 | – | – | 11,000 |
| Edward Hurwitz Director | May 20, 2025 | Option exercise | +6,500 | – | – | 44,074 |
| Meenu Chhabra Director | May 20, 2025 | Option exercise | +6,500 | – | – | 11,000 |
| Federica F. O'Brien Director | May 20, 2025 | Option exercise | +6,500 | – | – | 11,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MacroGenics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,558 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Karen Jean Ferrante Former Director | Oct 22, 2026 | 22,000 | $79.20K | Oct 22, 2026 | Stock Plan Activity |
| Thomas Spitznagel Former Officer | Sep 21, 2026 | 15,811 | $65.53K | Sep 21, 2026 | Stock plan activity |
| Jeffrey Stuart Peters Officer | Aug 19, 2026 | 31,105 | $129.15K | Aug 19, 2026 | Stock plan activity |
| Jay Philip Siegel Former Director | Aug 17, 2026 | 42,080 | $175.70K | Aug 17, 2026 | Stock plan activity |
| Jay Philip Siegel Former Director | Aug 3, 2026 | 34,916 | $130.94K | Aug 3, 2026 | Stock plan activity |
| Thomas Spitznagel Former Officer | Jul 13, 2026 | 17,000 | $75.53K | Jul 13, 2026 | Stock Plan Activity |
| Jeffrey Stuart Peters Officer | Apr 4, 2024 | 51,395 | $798.79K | Apr 4, 2024 | Stock Plan Activity |
| Jeffrey Stuart Peters Officer | Mar 6, 2024 | 19,625 | $411.88K | Mar 6, 2024 | Stock Plan Activity |
| Eric Blasius Risser Officer | Mar 4, 2024 | 41,159 | $815.61K | Mar 4, 2024 | Stock Plan Activity |
| Thomas Spitznagel Officer | Mar 4, 2024 | 10,000 | $199.99K | Mar 4, 2024 | Stock Plan Activity |
| James Karrels Officer | Mar 4, 2024 | 30,000 | $615.00K | Mar 4, 2024 | Exercised Options |
| Jeffrey Stuart Peters Officer | Feb 26, 2024 | 16,124 | $275.82K | Feb 26, 2024 | Stock Plan Activity |
| Ezio Bonvini Officer | Feb 7, 2024 | 3,334 | $60.00K | Feb 7, 2024 | Stock Plan Activity |
| Jeffrey Stuart Peters Officer | Feb 5, 2024 | 76,251 | $1.26M | Feb 5, 2024 | Stock Plan Activity |
| Ezio Bonvini Officer | Feb 1, 2024 | 13,316 | $199.73K | Feb 1, 2024 | Stock Plan Activity |
See a number that looks wrong?